research Does Post-Void Residual Volume Predict Worsening Urological Symptoms in Patients with Multiple Sclerosis?
Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
Search
for
Sort by
Research
30-60 / 1000+ results
research Discontinuation of Alpha-Blockade After Initial Treatment With Finasteride and Doxazosin for Bladder Outlet Obstruction
Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
research Prostate Cancer Prevention
Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
research A Regulatory Perspective on Pharmacokinetic/Pharmacodynamic Modelling
The document concludes that PK/PD modeling is important for determining the safe and effective dosages of drugs.
research Finasteride for Prostatic Disease: An Updated and Comprehensive Review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research SRD5A2 Expression Is a Predictor of Response to Finasteride in the MTOPS Trial
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research Five-Alpha-Reductase Inhibitors for Prostate Cancer Prevention
5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
research Dutasteride: A Review of Its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Inappropriate Sexual Behaviors in Patients with Vascular Dementia: Possible Response to Finasteride
Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
research Interactions Between Lower Urinary Tract Symptoms and Cardiovascular Risk Factors Determine Distinct Patterns of Erectile Dysfunction: A Latent Class Analysis
Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.
research Trends in the Development of New Drugs for the Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
research Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research 5-Alpha-Reductase Inhibitors for Prostate Cancer Chemoprevention: An Updated Cochrane Systematic Review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research Tamsulosin Treatment for Benign Prostatic Hyperplasia and Risk of Severe Hypotension in Men Aged 40-85 Years in the United States: Risk Window Analyses Using Between and Within Patient Methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research Combined Sabal And Urtica Extract Vs Finasteride In Benign Prostatic Hyperplasia (Alken Stage I–II)
Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.
research Finasteride
Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
research Emerging Medication for the Treatment of Male Hypogonadism
New treatments for male hypogonadism are effective and should be personalized.
research The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen, and Sexual Function in Healthy Young Men
Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
research Impact of Alpha Blockers, 5-Alpha Reductase Inhibitors, and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research 5-Alpha-Reductase Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research Saw Palmetto
Saw palmetto can help with prostate issues and may promote hair growth.
research Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial
Dutasteride can reduce night-time urination but it doesn't improve sleep quality.
research Comparison of Clinical Trials with Finasteride and Dutasteride
research The Role of Benign Prostatic Hyperplasia Treatments in Ejaculatory Dysfunction
Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
research Sleep Problems Are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE
Poor sleep is linked to a higher risk of developing and worsening urinary problems in men.
research The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.
research Association Between 5-Alpha Reductase Inhibitor Use and the Risk of Depression: A Meta-Analysis
Using 5-alpha reductase inhibitors may increase the risk of mild depression.
research Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction After Discontinuation of Finasteride
Men may experience long-term sexual dysfunction after stopping Finasteride.
research The Effect of Finasteride on the Expression of Vascular Endothelial Growth Factor and Microvessel Density: A Possible Mechanism for Decreased Prostatic Bleeding in Treated Patients
Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.
research Abstracts from the ASA 40th Annual Meeting
HNG may help prevent the negative effects of chemotherapy on sperm production and white blood cell counts.